Exciting news for all PMN shareholders!!!!Aducanumab approval has been stated as the key to unlocking our Phase I funding for PMN310, an antibody that is expected to be superior to aducanumab and other similar drugs in the pipeline for treating one of the largest unmet medical needs in the world.
Hold onto your hats PMN fans, we're about to hit the accelerator!
Congrats and glta!